Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2015
September 2015, Vol 6, No 8
September 2015, Vol 6, No 8
Controlled Ovarian Hyperstimulation Safe in Patients with Breast Cancer
By
Alice Goodman
Breast Cancer
,
Solid Tumors
September 2015, Vol 6, No 8
Boston, MA—Fertility preservation by controlled ovarian hyperstimulation with concurrent letrozole (Femara) is safe in women with breast cancer, according to a single-center, prospective study on the long-term safety of fertility preservation by the use of ovarian stimulation and concurrent aromatase inhibitors in women with breast cancer, presented at the 2015 Best of ASCO meeting in Boston. Controlled ovarian hyperstimulation had no impact on relapse-free survival and enabled live births in a substantial proportion of women who later chose to retrieve their frozen embryos or oocytes.
Read Article
Oncology Medical Home Accreditation by Community Oncology Alliance Making Progress
By
Wayne Kuznar
September 2015, Vol 6, No 8
Washington, DC—The Community Oncology Alliance (COA) is in the midst of developing an oncology medical home program. Ten oncology practices have participated in COA’s pilot program, and the oncology medical home model will be expanding to 50 more practices during 2016.
Read Article
Oncology Specialty Pharmacy Promotes the Coordination of Care
By
Wayne Kuznar
Specialty Pharmacy
September 2015, Vol 6, No 8
Washington, DC—The role of oncology specialty pharmacy in helping to streamline medication delivery for patients with cancer was the subject of a panel discussion that took place at the Fifth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
PROCLAIM Study Fails to Identify Best Regimen for Locally Advanced Lung Cancer
By
Alice Goodman
Lung Cancer
,
Solid Tumors
September 2015, Vol 6, No 8
Boston, MA—What is the best chemotherapy regimen to use for patients with locally advanced nonsquamous non–small-cell lung cancer (NSCLC)? The phase 3 PROCLAIM trial attempted to answer this question, but the study failed to determine the best regimen for this patient population.
Read Article
Challenges in Treating Multiple Myeloma and the Impact of New Oral Oncolytics
Interview with the Innovators
,
Multiple Myeloma
September 2015, Vol 6, No 8
An Interview with Dixie-Lee Esseltine, MD, and George Mulligan, PhD, of Takeda Pharmaceuticals Company
Read Article
SELECT: Lenvatinib Improves Outcomes as First-Line Treatment in Older Patients with Thyroid Cancer
By
Alice Goodman
Solid Tumors
,
Thyroid Cancer
September 2015, Vol 6, No 8
Chicago, IL—Lenvatinib (Lenvima) was approved by the FDA in February 2015 for the treatment of patients with advanced radioactive iodine (
131
I)-refractory differentiated thyroid cancer based on the SELECT trial results. Investigators looked at which patients will preferentially benefit from this oral tyrosine kinase inhibitor (TKI). At the 2015 American Society of Clinical Oncology meeting, 2 subgroup analyses of SELECT shed light on patient selection for treatment with lenvatinib.
Read Article
Immunotherapies Steal the Show at ASCO 2015
By
Chase Doyle
Immunotherapy
,
Personalized Medicine
September 2015, Vol 6, No 8
Chicago, IL—Oncologists looking to learn about immunotherapy did not have to go very far at the 2015 American Society of Clinical Oncology meeting. Many of the highest-impact presentations this year, including a plenary session, the Karnofsky Award, and the Science of Oncology Award, focused on cancer therapy’s most exciting field.
Read Article
Patients with Cancer Eager to Discuss Costs of Care with Their Oncologists
By
Laura Morgan
Economics & Value
,
Economics of Cancer Care
September 2015, Vol 6, No 8
Gone are the days when patients with cancer were, for the most part, protected from healthcare costs by their medical insurance. According to a recent study sponsored by the National Comprehensive Cancer Network and conducted by Ronan J. Kelly, MD, MBA, MBBCh, Assistant Professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, and colleagues, with high deductibles, escalating copayments, and cost-sharing requirements becoming the status quo, patients with cancer are now, more than ever, feeling the effects of financial toxicity, particularly young patients who are especially susceptible to filing for medical bankruptcy (Kelly RJ, et al.
J Oncol Pract
. 2015;11:308-312).
Read Article
In the Literature - September 2015
In the Literature
September 2015, Vol 6, No 8
Read Article
Medical and Psychosocial Impact of Oral Therapy on Patients with Metastatic Castration-Resistant Prostate Cancer
By
Laura Morgan
Prostate Cancer
,
Solid Tumors
September 2015, Vol 6, No 8
San Diego, CA—The introduction of 2 therapies for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC)—the orally administered abiraterone acetate (Zytiga) and enzalutamide (Xtandi)—has prompted Leslie Hazel-Fernandez, PhD, Comprehensive Health Insights, Louisville, KY, and colleagues to conduct a qualitative study to evaluate the personal and other factors that influence the use of oral drugs among patients with mCRPC, as well as to gauge caregivers’ and physicians’ experiences with patients who use these oral medications. The results of this study were presented at the 2015 Academy of Managed Care Pharmacy annual meeting.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Addressing Cancer Health Disparities: The No One Left Alone Initiative
Rohan Nathwani
,
Arva Patel
,
Warner Kornberg
,
Asutosh Gor, MD
,
Sashi Naidu, MD
,
Viral Rabara, MD
,
Niyati Nathwani, MD
,
Kashyap Patel, MD
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma